Replimune plans layoffs as FDA rejects cancer drug

Replimune (REPL) stock plunges as the company seeks layoffs following the FDA rejection of its cancer drug RP1 for melanoma.

Judge temporarily blocks Alberta’s chief electoral officer from certifying provincial ...

Court of King’s Bench Justice puts legal pause on the certification until she makes a ruling on the case brought forward by ...